Joseph Guenther, MD
Surgical Oncology · Edgewood, KYNPI 1790750172
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,155 of the $4,791 with a category attached, or 86.7%. 17 manufacturers reported payments, led by AstraZeneca at 48.5% of the total. Reporting peaked in 2021 at $4,266 and has fallen 95.7% since, to $183 in 2025.
Across 25 payments — averaging $191.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Merck$2K
- E.r. Squibb & Sons, L.L.C.$111
- Aroa Biosurgery Incorporated$105
- Tempus AI, Inc$100
- Lemaitre Vascular, Inc.$65
- plus $241 from 11 others
What the payments were for
- Consulting fees$4,15587%
- Food & beverage$63613%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $2,325 |
| Merck | 2 | $1,844 |
| E.r. Squibb & Sons, L.L.C. | 1 | $111 |
| Aroa Biosurgery Incorporated | 4 | $105 |
| Tempus AI, Inc | 1 | $100 |
| Lemaitre Vascular, Inc. | 1 | $65 |
| Avinger Inc. | 2 | $36 |
| Baxter Healthcare | 2 | $32 |
| Elucent Medical | 2 | $31 |
| Johnson & Johnson | 1 | $29 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Siemens Medical Solutions USA, Inc. | 1 | $18 |
| Heron Therapeutics, Inc. | 1 | $17 |
| Angiodynamics, Inc. | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Acell, Inc. | 1 | $13 |
| Coopersurgical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,791 in reported general payments places this provider in the 70th percentile of 29 surgical oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 518 | $10,334 |
| Tamoxifen Citrate | 144 | $4,322 |
| Oxybutynin Chloride ErOxybutynin Chloride | 12 | $277 |
| Letrozole | 13 | $248 |
| Tramadol Hcl | 159 | $197 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $70 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Edgewood
- Brent XiaEdgewood$3K
- Kelly MackessyEdgewood$243
- Robert MartinLouisville$483K
- Jennifer WhittingtonLexington$22K
- Charles ScogginsLouisville$15K
- Nicolas AjkayLouisville$11K
- Prejesh PhilipsLouisville$9K
- Prakash PandalaiLexington$8K
- Daniel KenadyHazard$6K
- Mary HughesAshland$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.